Status:

RECRUITING

Efficacy and Safety of Vaginal Radiofrequency for Vulvovaginal Atrophy in Breast Cancer Patients

Lead Sponsor:

Centre Oscar Lambret

Collaborating Sponsors:

MATMATECH

Conditions:

Vaginal Dryness

Breast Cancer

Eligibility:

FEMALE

40+ years

Phase:

NA

Brief Summary

This Phase III, randomized, balanced, parallel-group, multicenter trial aims to evaluate the effect of vaginal radiofrequency on symptoms of vaginal dryness at six months. The study compares vaginal r...

Detailed Description

This study aims to see if vaginal radiofrequency therapy can help reduce vaginal dryness in women receiving hormone therapy for breast cancer. The participants are divided into two groups: One group...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA :
  • Patient over 40 years
  • Presenting disabling vaginal dryness symptoms despite well-administered local moisturizing treatment, attested by a vaginal dryness score ≥3
  • Patient undergoing adjuvant treatment for breast cancer
  • Patient treated with aromatase inhibitors +/- LHRH agonist for at least 3 months with a planned remaining duration of at least 12 months
  • Patient affiliated to a social security organization
  • Patient having signed the informed consent for the present study
  • EXCLUSION CRITERIA:
  • Contraindications related to the radiofrequency technique:
  • Ongoing urinary tract infection
  • Pacemaker
  • IUD intrauterine device
  • Pregnancy
  • Mucocutaneous disease with vulvovaginal localization: infection, sore, scleratrophic lichen, psoriasis, eczema, etc.
  • Neurodegenerative disease with perineal involvement
  • Current or recent treatment (within the last 12 months) with other physical methods: vaginal laser, photobiomodulation, PRP injection, hyaluronic acid injection or lipo-modeling.
  • Pregnant or breast-feeding women
  • Patients under guardianship or trusteeship.

Exclusion

    Key Trial Info

    Start Date :

    June 15 2025

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    June 1 2028

    Estimated Enrollment :

    75 Patients enrolled

    Trial Details

    Trial ID

    NCT06900374

    Start Date

    June 15 2025

    End Date

    June 1 2028

    Last Update

    September 26 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Centre Oscar Lambret

    Lille, France, 59020